BA
TBRA

BlackRock Advisors’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

BlackRock Advisors’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,418
Closed -$136K – 3801
2016
Q3 		$136K Buy
3,418
+1,026
+43% +$11.4K ﹤0.01% 2884
2016
Q2 		$30K Sell
2,392
-2,154
-47% -$20.1K ﹤0.01% 3354
2016
Q1 		$37K Sell
4,546
-6,903
-60% -$52.1K ﹤0.01% 3262
2015
Q4 		$115K Buy
11,449
+1,693
+17% +$17.6K ﹤0.01% 2861
2015
Q3 		$94K Buy
9,756
+8,517
+687% +$120K ﹤0.01% 3130
2015
Q2 		$21K Buy
1,239
+520
+72% +$7.6K ﹤0.01% 3506
2015
Q1 		$8K Hold
719
– – ﹤0.01% 3549
2014
Q4 		$6K Hold
719
– – ﹤0.01% 3639
2014
Q3 		$7K Sell
719
-8,038
-92% -$159K ﹤0.01% 3611
2014
Q2 		$535K Buy
+8,757
New +$533K ﹤0.01% 1975

BlackRock Advisors's TBRA Position: Q4 2016 in Review

BlackRock Advisors sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 3,418 shares — an estimated $136K sold.

BlackRock Advisors first reported a position in TBRA in Q2 2014 and held it in 10 quarters. The position peaked at $535K in Q2 2014. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

  • BlackRock Advisors reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • BlackRock Advisors sold 3,418 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $136K.
  • BlackRock Advisors first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 10 quarters.
  • BlackRock Advisors's Tobira Therapeutics, Inc. Common Stock position peaked at $535K in Q2 2014.
  • 0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.